Back to Search Start Over

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature.

Authors :
Vita S
Rosati S
Ascoli Bartoli T
Beccacece A
D'Abramo A
Mariano A
Scorzolini L
Goletti D
Nicastri E
Source :
Pathogens (Basel, Switzerland) [Pathogens] 2022 Aug 05; Vol. 11 (8). Date of Electronic Publication: 2022 Aug 05.
Publication Year :
2022

Abstract

Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have already authorized monoclonal antibodies of anti-SARS-CoV-2 to treat mild to moderate CoronaVIrus Disease-2019 (COVID-19) in patients at risk of developing severe disease. More recently, monoclonal antibodies anti-SARS-CoV-2 have been authorized for primary and secondary prophylaxis in patients at high risk of severe disease for background comorbidity. Primary or pre-exposure prophylaxis prevents COVID-19 in unexposed people, whereas secondary or postexposure prophylaxis prevent COVID-19 in recently exposed people to individuals with laboratory-confirmed SARS-CoV-2. This review focuses briefly on therapeutic indications of currently available monoclonal antibodies for COVID-19 pre- and postexposure prophylaxis and on the efficacy of convalescent plasma.

Details

Language :
English
ISSN :
2076-0817
Volume :
11
Issue :
8
Database :
MEDLINE
Journal :
Pathogens (Basel, Switzerland)
Publication Type :
Academic Journal
Accession number :
36015003
Full Text :
https://doi.org/10.3390/pathogens11080882